Literature DB >> 6454075

Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts.

A B Cosimi, R B Colvin, R C Burton, R H Rubin, G Goldstein, P C Kung, W P Hansen, F L Delmonico, P S Russell.   

Abstract

Using monoclonal antibodies and flow cytometry, wer serially monitored lymphocyte subpopulations in renal-allograft recipients treated with either conventional immunosuppression or a monoclonal antibody. In 29 patients given conventional suppression, highly significant correlations between changes in T-cell subsets and rejection were noted. Normal or elevated ratios of OKT4 (helper/inducer) to OKT8 (suppressor/cytotoxic) cells were associated with rejection unless the donor was HLA identical or the total number of T cells was extremely low. In patients with low ratios, rejection seldom occurred. Two patients treated with OKT3 monoclonal antibody for acute rejection had rapid disappearance of OKT3-reactive cells from the peripheral blood and prompt reversal of rejection. The use of monoclonal antibodies allows the precise determination of changes in T-cell subsets and promises the development of therapeutic protocols that can be designed to manipulate selected lymphocyte populations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6454075     DOI: 10.1056/NEJM198108063050603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  88 in total

1.  History of clinical transplantation.

Authors:  T E Starzl
Journal:  World J Surg       Date:  2000-07       Impact factor: 3.352

2.  Coronary bypass surgery after renal transplantation.

Authors:  H Noda; Y Fujimura; H Gohra; K Hamano; T Katoh; K Esato
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-03

3.  Cytokine release and dynamics of leukocyte populations after CD3/TCR monoclonal antibody treatment.

Authors:  G J Zlabinger; K M Stuhlmeier; R Eher; S Schmaldienst; R Klauser; A Vychytil; B Watschinger; O Traindl; J Kovarik; E Pohanka
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

4.  Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications.

Authors:  Veronica Marrella; Pietro L Poliani; Elena Fontana; Anna Casati; Virginia Maina; Barbara Cassani; Francesca Ficara; Manuela Cominelli; Francesca Schena; Marianna Paulis; Elisabetta Traggiai; Paolo Vezzoni; Fabio Grassi; Anna Villa
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

Review 5.  The present state of liver transplantation and the future prospects for intestinal transplantation.

Authors:  T E Starzl
Journal:  Immunol Invest       Date:  1989 Jan-May       Impact factor: 3.657

6.  Mobility of the human T lymphocyte surface molecules CD3, CD4, and CD8: regulation by a cAMP-dependent pathway.

Authors:  G M Kammer; C A Boehm; S A Rudolph; L A Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

7.  Immunotherapy for infectious diseases.

Authors:  J E Pennington
Journal:  West J Med       Date:  1990-04

8.  Allergy-epitomes of progress: monoclonal antibodies.

Authors:  R D O'Connor
Journal:  West J Med       Date:  1982-08

9.  Acute rejection in heart transplant patients is associated with the presence of committed donor-specific cytotoxic lymphocytes in the graft but not in the blood.

Authors:  L M Vaessen; C C Baan; A J Ouwehand; N H Jutte; A H Balk; B Mochtar; F H Claas; W Weimar
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

10.  Local immunosuppressive therapy with monoclonal anti-T cell antibody on renal allograft survival in the rat.

Authors:  C J Lee; N Yoshimura; O Shiho; M Kita; T Oka
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.